Natco Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE987B01026
  • NSEID: NATCOPHARM
  • BSEID: 524816
INR
817.00
-4.5 (-0.55%)
BSENSE

Nov 20

BSE+NSE Vol: 6.23 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Corona Remedies
Alivus Life
Caplin Point Lab
Shilpa Medicare
Sudeep Pharma
Astrazeneca Phar
OneSource Speci.
Cohance Life
Jubilant Pharmo
Pfizer
Natco Pharma
Why is Natco Pharma Ltd. ?
1
With a fall in Net Profit of -29.18%, the company declared Very Negative results in Sep 26
  • The company has declared negative results for the last 4 consecutive quarters
  • PAT(Q) At Rs 202.60 cr has Fallen at -29.2% (vs previous 4Q average)
  • NET SALES(Latest six months) At Rs 1,702.50 cr has Grown at -36.75%
  • ROCE(HY) Lowest at 7.27%
2
Stock is technically in a Mildly Bearish range
  • A key technical factor - MACD has been Bearish since 06 Nov 2026
3
Below par performance in long term as well as near term
  • Along with generating -5.26% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Natco Pharma for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Natco Pharma
-5.26%
-0.14
36.28%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
15.95%
EBIT Growth (5y)
20.66%
EBIT to Interest (avg)
54.62
Debt to EBITDA (avg)
0.46
Net Debt to Equity (avg)
-0.05
Sales to Capital Employed (avg)
0.51
Tax Ratio
8.81%
Dividend Payout Ratio
5.70%
Pledged Shares
0.94%
Institutional Holding
26.18%
ROCE (avg)
21.71%
ROE (avg)
16.74%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
19
Industry P/E
40
Price to Book Value
1.63
EV to EBIT
28.73
EV to EBITDA
21.14
EV to Capital Employed
1.66
EV to Sales
5.00
PEG Ratio
NA
Dividend Yield
0.66%
ROCE (Latest)
5.79%
ROE (Latest)
8.48%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company
OPERATING CF(Y)

Highest at Rs 1,776.40 Cr

-31What is not working for the Company
PAT(Q)

At Rs 202.60 cr has Fallen at -29.2% (vs previous 4Q average

NET SALES(Latest six months)

At Rs 1,702.50 cr has Grown at -36.75%

ROCE(HY)

Lowest at 7.27%

INVENTORY TURNOVER RATIO(HY)

Lowest at 3.07 times

DEBT-EQUITY RATIO(HY)

Highest at 0.11 times

INTEREST(Q)

Highest at Rs 17.60 cr

PBT LESS OI(Q)

At Rs 191.10 cr has Fallen at -5.6% (vs previous 4Q average

Loading Valuation Snapshot...
Here's what is working for Natco Pharma
Operating Cash Flow - Annually
Highest at Rs 1,776.40 Cr and Grown
each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (Rs Cr)

Here's what is not working for Natco Pharma
Profit After Tax (PAT) - Quarterly
At Rs 202.60 cr has Fallen at -29.2% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 286.08 Cr
MOJO Watch
Near term PAT trend is very negative

PAT (Rs Cr)

Interest - Quarterly
At Rs 17.60 cr has Grown at 35.38%
Quarter on Quarter (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Net Sales - Latest six months
At Rs 1,702.50 cr has Grown at -36.75%
Year on Year (YoY)
MOJO Watch
Near term sales trend is negative

Net Sales (Rs Cr)

Inventory Turnover Ratio- Half Yearly
Lowest at 3.07 times and Fallen
each half year in the last five half yearly periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Interest - Quarterly
Highest at Rs 17.60 cr
in the last five quarters and Increased by 35.38 % (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 191.10 cr has Fallen at -5.6% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 202.35 Cr
MOJO Watch
Near term PBT trend is negative

PBT less Other Income (Rs Cr)

Debt-Equity Ratio - Half Yearly
Highest at 0.11 times
in the last five half yearly periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio